<DOC>
	<DOCNO>NCT01804010</DOCNO>
	<brief_summary>1 . To assess pharmacokinetic profile ivabradine ( S 16257 ) main active metabolite S 18982 Korean healthy volunteer oral administration ivabradine dose 2.5 , 5 , 10mg repeat oral administration ivabradine 4.5 day dos twice daily versus placebo use study result bridge Caucasian data . 2 . The pharmacodynamic profile ivabradine versus placebo measure effect heart rate single repeat administration . 3 . Clinical safety ivabradine versus placebo .</brief_summary>
	<brief_title>Pharmacokinetic , Pharmacodynamic Profiles Safety After Oral Administration Ivabradine Male Healthy Korean Volunteers</brief_title>
	<detailed_description />
	<criteria>age 18 40 year Korean Nonsmoker smoke less 5 cigarette per day normal dietary habit BMI range 18 25 kg/m2 good physical mental status , determine investigator vital sign rest condition within range : SBP 100139 mmHg , DBP 5089 mmHg Normal ECG Participate trial last 3 month prior study History major psychiatric , medical , surgical disorder Acute , chronic disease History hypersensitivity least one drug History alcoholism positive alcohol breath test Positive drug screen result know positive serology HIV1 , HIV2 , hepatitis B C blood donor within last 3 month study regular use sedative , hypnotic , tranquilliser</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>